Targeted therapies for ALL
| Therapy . | Description . |
|---|---|
| CD20 | |
| Rituximab | When added to conventional chemotherapy has been shown to improve survival in younger adults |
| Ofatumumab | Binds to a different epitope than rituximab, which may allow it to overcome rituximab-resistant disease |
| Obinutuzumab | Novel glycoengineered type II CD20 monoclonal antibody superior to rituximab and ofatumumab in the induction of direct cell death. |
| CD19 | |
| SAR3419 | Conjugated to a synthetic maytansinoid that is release intracellularly after antigen internalization |
| SGN-CD19A | Humanized anti-CD19 monoclonal antibody conjugated to the microtubule-disrupting agent. On internalization, it binds to tubulin and induces G2/M arrest and apoptosis |
| Blinatumomab | Bispecific antibody that redirects cytotoxic T cells to cells that express CD19 |
| CD22 | |
| Epratuzumab | Studied as part of combination therapy in adults and children with modest activity |
| Epratuzumab-SN38 | Antibody conjugated to a topoisomerase I inhibitor to enhance cell killing potential |
| Inotuzumab ozogamicin | Antibody conjugated to the cytotoxin calicheamicin |
| Moxetumomab | Antibody conjugated to bacterial or plant toxin |
| CD52 | |
| Alemtuzumab | Antibody that has only displayed little activity in B- and T-cell disease |
| Therapy . | Description . |
|---|---|
| CD20 | |
| Rituximab | When added to conventional chemotherapy has been shown to improve survival in younger adults |
| Ofatumumab | Binds to a different epitope than rituximab, which may allow it to overcome rituximab-resistant disease |
| Obinutuzumab | Novel glycoengineered type II CD20 monoclonal antibody superior to rituximab and ofatumumab in the induction of direct cell death. |
| CD19 | |
| SAR3419 | Conjugated to a synthetic maytansinoid that is release intracellularly after antigen internalization |
| SGN-CD19A | Humanized anti-CD19 monoclonal antibody conjugated to the microtubule-disrupting agent. On internalization, it binds to tubulin and induces G2/M arrest and apoptosis |
| Blinatumomab | Bispecific antibody that redirects cytotoxic T cells to cells that express CD19 |
| CD22 | |
| Epratuzumab | Studied as part of combination therapy in adults and children with modest activity |
| Epratuzumab-SN38 | Antibody conjugated to a topoisomerase I inhibitor to enhance cell killing potential |
| Inotuzumab ozogamicin | Antibody conjugated to the cytotoxin calicheamicin |
| Moxetumomab | Antibody conjugated to bacterial or plant toxin |
| CD52 | |
| Alemtuzumab | Antibody that has only displayed little activity in B- and T-cell disease |